(HealthDay News) – In men with complete erectile dysfunction (ED), tadalafil 2.5mg and 5mg once-daily result an in intercourse success rate of 32.4% and 46.4%, respectively, according to research published online Oct 4 in The Journal of Sexual Medicine.
Ridwan Shabsigh, MD, of the Maimonides Medical Center in New York City, and colleagues conducted a post-hoc, pooled analysis of results from four randomized, double-blind trials evaluating the effects of tadalafil 2.5mg or 5mg compared with placebo in men with complete ED (no successful intercourse attempts at baseline).
After 12 weeks of once-daily treatment with tadalafil, the researchers found that the mean per-patient Sexual Encounter Profile question 3 (SEP3) increased from 0% to 32.4% and 46.4% with 2.5mg and 5mg tadalafil, respectively. The SEP2 (successful penetration) increased from 21.1% to 48.2% and 24.4% to 66.2% with 2.5mg and 5mg tadalafil, respectively. The mean International Index of Erectile Function increased significantly with 2.5mg and 5mg tadalafil vs. placebo. Compared with placebo, improvements were also noted in intercourse-satisfaction and overall-satisfaction domains. Tadalafil was well tolerated with no increase in adverse events vs. placebo.
“Once-daily tadalafil 2.5mg or 5mg significantly enhanced erectile function (vs. placebo) across all coprimary and secondary efficacy end points in this analysis, and was generally well tolerated,” the authors write.
The four base studies and the reported analysis were sponsored by Eli Lilly; several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures tadalafil.